These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1043 related items for PubMed ID: 19463351

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
    Faxon DP, Lawler E, Young M, Gaziano M, Kinlay S.
    Circ Cardiovasc Interv; 2012 Jun; 5(3):372-80. PubMed ID: 22668555
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ.
    JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y, Kukreja N, Daemen J, Garcia-Garcia HM, Gonzalo N, Cheng JM, van Twisk PH, van Domburg R, Serruys PW, Interventional Cardiologists of Thoraxcenter.
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [Abstract] [Full Text] [Related]

  • 7. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA, Rathod KS, Gallagher S, Weerackody R, Knight CJ, Rothman MT, Mathur A, Jain AK, Timmis AD, Wragg A.
    Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
    [Abstract] [Full Text] [Related]

  • 8. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.
    Barthelemy O, Helft G, Silvain J, Bellemain-Appaix A, Beygui F, Choussat R, Berman E, Collet JP, Montalescot G, Metzger JP, Le Feuvre C.
    Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW, Interventional Cardiologists of the Thoraxcenter.
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [Abstract] [Full Text] [Related]

  • 11. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
    Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T, CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators.
    Circ Cardiovasc Interv; 2012 Jun; 5(3):381-91. PubMed ID: 22619260
    [Abstract] [Full Text] [Related]

  • 12. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, Bradshaw B, Humphrey A, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Simonton CA, STENT Group.
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
    Hannan EL, Racz M, Walford G, Holmes DR, Jones RH, Sharma S, Katz S, King SB.
    JACC Cardiovasc Interv; 2008 Apr; 1(2):129-35. PubMed ID: 19463290
    [Abstract] [Full Text] [Related]

  • 15. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
    Leon MB, Allocco DJ, Dawkins KD, Baim DS.
    JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
    [Abstract] [Full Text] [Related]

  • 16. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
    Naidu SS, Krucoff MW, Rutledge DR, Mao VW, Zhao W, Zheng Q, Wilburn O, Sudhir K, Simonton C, Hermiller JB.
    JACC Cardiovasc Interv; 2012 Jun; 5(6):626-35. PubMed ID: 22721657
    [Abstract] [Full Text] [Related]

  • 17. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
    Sarafoff N, Sibbing D, Sonntag U, Ellert J, Schulz S, Byrne RA, Mehilli J, Schömig A, Kastrati A.
    Thromb Haemost; 2010 Sep; 104(3):626-32. PubMed ID: 20664905
    [Abstract] [Full Text] [Related]

  • 18. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
    Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Stanco G, Rosato G, Suryapranata H, De Luca G.
    JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
    [Abstract] [Full Text] [Related]

  • 19. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.
    Kukreja N, Onuma Y, Garcia-Garcia HM, Daemen J, van Domburg R, Serruys PW, Interventional Cardiologists of the Thoraxcenter (2000 to 2005).
    JACC Cardiovasc Interv; 2009 Jun; 2(6):534-41. PubMed ID: 19539258
    [Abstract] [Full Text] [Related]

  • 20. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, Cowper PA, Kong DF, Anstrom KJ.
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.